Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent
BD Klugherz, G Llanos, W Lieuallen… - Coronary artery …, 2002 - journals.lww.com
Background In-stent restenosis is caused by neointimal hyperplasia. Sirolimus (rapamycin;
Wyeth Research, Radnor, Pennsylvania, USA) inhibits vascular smooth muscle cell
proliferation and we evaluated the efficacy of sirolimus in reducing neointimal formation in a
rabbit iliac model and in-vivo pharmacokinetics in the porcine coronary model. Design
Wyeth Research, Radnor, Pennsylvania, USA) inhibits vascular smooth muscle cell
proliferation and we evaluated the efficacy of sirolimus in reducing neointimal formation in a
rabbit iliac model and in-vivo pharmacokinetics in the porcine coronary model. Design